Page 3 - ஈர் வெளிப்புறம் தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஈர் வெளிப்புறம் தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஈர் வெளிப்புறம் தகவல்தொடர்புகள் Today - Breaking & Trending Today

Achilles Therapeutics PLC: Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting


(0)
LONDON, April 10, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Company s ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2021. Through a comprehensive translational research program, data from Patient T-05 offer insight into the
in vivo dynamics of clonal neoantigen T cells (cNeT) post-dosing and the potential to develop a potency-based release assay.
As we move through our Phase I/IIa THETIS and CHIRON clinical programs in metastatic melanoma and advanced non-small cell lung cancer, it is important to quantify and characterize cNeT, the active component in our precision T cell therapy, prior to and after cell infusion, said ....

United States , City Of , United Kingdom , Sergio Quezada , Melissa Gardiner , Mary Jane Elliott , Sukaina Virji , American Association For Cancer Research , Consilium Strategic Communications , Ir External Communications , American Association , Cancer Research , Annual Meeting , Chief Scientific Officer , Session Category , Adoptive Cell , Jane Elliott , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , செர்ஜியோ க்வெஸாட , மெலிசா தோட்டக்காரர் , மேரி ஜேன் எலியட் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் , ஈர் வெளிப்புறம் தகவல்தொடர்புகள் ,

Investegate |Syncona Limited Announcements | Syncona Limited: Achilles data and safety committee review


05 February 2020
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. 
The full text announcement is contained below and can be accessed on Achilles website at:
https://achillestx.com/news
.
 
 
Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of Syncona Limited. These statements and forecasts involve risk and uncertain ....

United Kingdom , City Of , Karl Peggs , Miraj Ali , Collins Tim Stamper , Annabel Clay , Ben Atwell Natalie , Company Clonal Neoantigen Targeting , Safety Monitoring Committee , Syncona Ltd , Ir External Communications , Syncona Limited , Announces Positive Independent Data , Achilles Therapeutics , Independent Data , Natalie Garland Collins , Therapeutics Announces Positive Independent Data , Safety Monitoring Committee Review , Current Study Design , Chief Executive Officer , Chief Medical Officer , Investegate Announcements , Investegate Company Announcements , Regulatory News Service , Regulatory News Service And , ஒன்றுபட்டது கிஂக்டம் ,

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials


Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials
Phase I/IIa CHIRON and THETIS Trials
London, UK 5 February 2021 - Achilles Therapeutics ( Achilles or the Company ), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/IIa CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. In this review of the first six patients dosed with the Company s Clonal Neoantigen Targeting T cell therapy (cNeTs), the overall tolerability profile was generally similar to that of standard tumor-infiltrating lymphocyte (TIL) products that have not been enriched for cNeT reactivities, with the lymphodepletion re ....

United Kingdom , City Of , Karl Peggs , Kostenloser Wertpapierhandel , Melissa Gardiner , Miraj Ali , Mary Jane Elliott , Sukaina Virji , Company Clonal Neoantigen Targeting , Safety Monitoring Committee , Consilium Strategic Communications , Ir External Communications , Achilles Therapeutics Announces Independent Data , Safety Monitoring Committee Review , Positive Recommendation , Current Study Design , Independent Data , Chief Executive Officer , Chief Medical Officer , Jane Elliott , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , கார்ல் பேக்க்ஸ் , மெலிசா தோட்டக்காரர் , இராஜ் அலி , மேரி ஜேன் எலியட் ,